Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Boehringer Ingelheim
Medtronic
McKinsey
Johnson and Johnson

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR NAMENDA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Namenda

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00120874 ↗ Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed Fisher Center for Alzheimer's Research Foundation Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗ Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed Forest Laboratories Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗ Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed New York University School of Medicine Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗ Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed NYU Langone Health Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00181298 ↗ Memantine in Systemic Lupus Erythematosus Completed Forest Laboratories N/A 2006-03-01 Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Namenda

Condition Name

Condition Name for Namenda
Intervention Trials
Alzheimer's Disease 6
Autism 4
Autism Spectrum Disorder 4
Obsessive-Compulsive Disorder 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Namenda
Intervention Trials
Disease 13
Cognitive Dysfunction 10
Autistic Disorder 8
Alzheimer Disease 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Namenda

Trials by Country

Trials by Country for Namenda
Location Trials
United States 243
Canada 5
Spain 4
Korea, Republic of 4
Ukraine 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Namenda
Location Trials
California 18
Massachusetts 17
New York 16
Illinois 10
Maryland 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Namenda

Clinical Trial Phase

Clinical Trial Phase for Namenda
Clinical Trial Phase Trials
Phase 4 22
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Namenda
Clinical Trial Phase Trials
Completed 50
Recruiting 6
Terminated 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Namenda

Sponsor Name

Sponsor Name for Namenda
Sponsor Trials
Forest Laboratories 28
Massachusetts General Hospital 10
National Cancer Institute (NCI) 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Namenda
Sponsor Trials
Other 95
Industry 31
NIH 12
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Boehringer Ingelheim
Harvard Business School
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.